Scancell Holdings (GB:SCLP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scancell Holdings Plc, a developer of novel immunotherapies for cancer, is set to present significant clinical data at the 21st CIMT Annual Meeting in Mainz, Germany. The company will showcase an oral presentation on its DNA plasmid melanoma cancer vaccine, SCIB1, as well as poster presentations on T cell receptor isolation and CAR-T cell therapy targeting gastrointestinal tumors. These presentations underscore Scancell’s commitment to advancing cancer treatment through its proprietary technology platforms.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.